The abstract is read at the publisher; the summary is JClub's.
In premenopausal hormone receptor-positive early breast cancer, 15-year breast cancer-free interval is highest with exemestane plus ovarian function suppression (78.6%) versus tamoxifen plus OFS (75.7%) and tamoxifen alone (72.1%).
- Why it matters: Long-term benefit beyond earlier reports is needed to define which premenopausal subgroups gain meaningful reductions in recurrence and mortality from adding ovarian function suppression and choosing exemestane.
- What they did: SOFT (n=3047) and TEXT (n=2660) randomized women to 5 years of tamoxifen-based endocrine therapy with or without OFS, and compared tamoxifen+OFS versus exemestane+OFS; outcomes included 15-year Kaplan-Meier estimates, hazard ratios, and 95% confidence intervals.
- The result: Across SOFT and TEXT, in HER2-negative tumors (n=4035), exemestane+OFS reduced distant recurrence versus tamoxifen+OFS (HR 0.75, 95% CI 0.63–0.90) with a smaller, non-significant death reduction (HR 0.89, 95% CI 0.74–1.06), with largest absolute survival benefits in high-risk features.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.